Qiagen Claims Market Leadership in HPV Testing as Molecular Dx Business Drives Q2 Revenue Growth
August 12, 2010
Qiagen Claims Market Leadership in HPV Testing as Molecular Dx Business Drives Q2 Revenue Growth
In a conference call to discuss its second-quarter earnings, the company told investors that it will delay the anticipated launch time of its higher throughput and fully automated QIAensemble Revolution platform for HPV and other molecular testing in an effort to make it more amenable to centralized testing labs.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Gen-Probe Sees Specificity of Newly Approved HPV Test as Market Differentiator
November 3, 2011 / PCR Insider - Hologic Women's Health Deal with Quest Viewed as Loss for Qiagen, Particularly on HPV Front
June 13, 2013 / PCR Insider - IP Watch: Hologic, Roche, Qiagen, Life Tech, Alere, Genaphora, Others Win US Patents
June 11, 2013 / PCR Insider - Qiagen, Roche See Good News in Changes to HPV Testing Guidelines
March 15, 2012 / GenomeWeb Daily News - OncoHealth Takes on HPV Testing Market with Protein-Based Assay
December 7, 2011 / GenomeWeb Daily News